3: Medication Assisted Treatment Centers, Substance Use Disorders, and HIV
Details
Description
This virtual event is the third in the series entitled "Intersecting Epidemics in the Context of Ending the Epidemic: Tackling HIV, Substance Use, and HCV". This series is co-sponsored by the MidAtlantic AIDS Education and Training Center (MAAETC), the National Alliance for HIV Education and Workforce Development (NAHEWD), the Opioid Response Network (ORN), the Mid-Atlantic Regional Public Health Training Center, and the Central East Addiction Technology Transfer Center (ATTC).
Session Title: Medication Assisted Treatment Centers, Substance Use Disorders, and HIV
Audience: health care providers and staff working at HIV clinics, infectious disease clinics, substance use disorder treatment programs, opioid treatment programs, case managers, addiction counselors and therapists.
- 11:30am ET – Attendees sign on and will be put in the waiting room
- 11:40am ET - Attendees are admitted to the webinar from the waiting room.
- 11:45am ET – technical/logistics overview
- 11:55am ET – speaker introduction
- 12:00pm ET-12:50pm ET – didactic PPT presentation by Ingrid McDowell
- 12:50pm ET-1:00pm ET – Audience full group Q&A
- 1:00pm ET-1:45pm ET – Panel discussion featuring different MAT centers
- 1:45pm ET-1:58pm ET – Final summary/questions
- 1:58pm ET-2:00pm ET– Concluding remarks, evaluation
Session objectives:
By the end of the session, participants will be able to:
- Discuss how to screen for HIV minimizing stigma as a barrier to care and engagement
- Identify opportunities to offer HIV treatment and HIV prevention such as PrEP in conjunction with treatment for substance use disorder
- Describe methods to provide HIV treatment and HIV prevention such as PrEP in facilities that focus on treating substance use disorder
Accreditation:
To be eligible to receive any credit for attending this event, you must attend the event in its entirety and complete all required evaluations.
Nursing: The MidAtlantic AIDS Education and Training Center is approved as a provider of nursing continuing professional development by the Pennsylvania State Nurses Association Approver Unit an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.
Social Work: This program is offered for 2.0 CE hours of social work continuing education through co-sponsorship of the University of Pittsburgh's School of Social Work, a Council on Social Work Education accredited school and therefore a PA pre-approved provider of social work continuing education. These credit hours satisfy requirements for LSW/LCSW, LMFT, and LPC biennial license renewal.
Continuing Medical Education (CME): This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Pittsburgh School of Medicine and MidAtlantic AIDS Education and Training Center. The University of Pittsburgh School of Medicine accredited by the ACCME to provide continuing medical education for physicians. The University of Pittsburgh School of Medicine designates this live activity for 2.25 AMA PRA Category 1 Credit™.
Addiction Treatment Professionals: Central East ATTC is a NAADAC approved continuing education provider and has approved up to 2.0 contact hours for this event.
Continuing Education credits issued for participation in CE activity may not apply toward license renewal in all states. It is the responsibility of each participant to verify the requirements of their state licensing board(s).
Targeted Populations
A variety of the listed populations will be discussed at this event.
- people with SUD
Materials
Topics
A variety of the listed topics will be discussed at this event.
- Harm Reduction/Safe Injection
- HIV Transmission Risk Assessment
- Antiretroviral treatment adherence, including viral load suppression
- HIV diagnosis (i.e. HIV testing)
- Linkage to Care
- Hepatitis C
- Medication-assisted therapy for substance use disorders (i.e. buprenorphine, methadone, and/or naltrexone)
- Substance use disorders
- Opioid use disorder